Compare
MoonLake Immunotherapeutics vs Stoke Therapeutics, Inc. vs Bicara Therapeutics Inc. vs Arcutis Biotherapeutics, Inc.
| Latest fiscal year | MoonLake Immunotherapeutics MLTX | Stoke Therapeutics, Inc. STOK | Bicara Therapeutics Inc. BCAX | Arcutis Biotherapeutics, Inc. ARQT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $184.42M | n/a | $372.07M |
| Revenue growth (YoY) | n/a | +404.5% | n/a | +123.4% |
| Gross margin | n/a | n/a | n/a | 90.1% (computed) |
| Operating margin | n/a | -11.2% | n/a | -3.3% |
| Net margin | n/a | -3.7% | n/a | -4.3% |
| Net income | -$227.32M | -$6.88M | -$137.95M | -$16.14M |
| EPS (Diluted) | -$3.53 | -$0.12 | -$2.52 | -$0.13 |
| Operating cash flow | -$196.01M | $45.59M | -$106.83M | -$5.62M |
| Free cash flow | -$196.04M | $44.91M | -$107.11M | -$6.31M |
| Cash & equivalents | $334.52M | $84.22M | $96.69M | $42.91M |
| Total assets | $424.43M | $418.43M | $430.99M | $432.97M |
| Total liabilities | $119.95M | $65.98M | $29.54M | $243.49M |
| Shareholders' equity | $304.48M | $352.46M | $401.45M | $189.48M |
| Return on year-end equity | -74.7% | -2.0% | -34.4% | -8.5% |
| Shares outstanding | n/a | 58.92M | 56.60M | 123.33M |
Revenue, most recent five fiscal years
| Fiscal year | MoonLake Immunotherapeutics | Stoke Therapeutics, Inc. | Bicara Therapeutics Inc. | Arcutis Biotherapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $184.42M Ended 2025-12-31 | n/a | $372.07M Ended 2025-12-31 |
| 1 year earlier | n/a | $36.55M Ended 2024-12-31 | n/a | $166.54M Ended 2024-12-31 |
| 2 years earlier | n/a | $8.78M Ended 2023-12-31 | n/a | $59.61M Ended 2023-12-31 |
| 3 years earlier | n/a | $12.40M Ended 2022-12-31 | n/a | $3.69M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $0 Ended 2021-12-31 |